KAITLIN CORES: Open Payments
NPI 1558518050 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,506 in 158 payments from 16 companies in 2025. Trend: 2023 $2,224 · 2024 $2,288 · 2025 $2,506
Food & beverage: $2,506
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 27 | $469 |
| Janssen Pharmaceuticals, Inc | 14 | $237 |
| ABBVIE INC. | 19 | $219 |
| Corium, LLC | 16 | $217 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $213 |
| Vanda Pharmaceuticals Inc. | 13 | $204 |
| E.R. Squibb & Sons, L.L.C. | 16 | $190 |
| Supernus Pharmaceuticals, Inc. | 10 | $163 |
| Bausch Health US, LLC | 7 | $150 |
| Axsome Therapeutics, Inc. | 7 | $138 |
Products named: ARISTADA, VRAYLAR, Azstarys, CAPLYTA, FANAPT, COBENFY, Qelbree, APLENZIN.
Industry payments across OK — which companies pay providers there.
